Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor

British Journal of Pharmacology

Volumn 139, Issue 4, 2003, Pages 775-786

  Klegeris, Andis ^a   Bissonnette, Christopher J ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Cannabinoid receptors; Cytokines; Human microglia; Inflammation; Marijuana; Multiple sclerosis; Neuroprotection; SH SY5Y neuroblastoma cells; THP 1 monocytic cells

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ANANDAMIDE; BML 190; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYTOKINE; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; GAMMA INTERFERON; INDOMETHACIN MORPHOLINYLAMIDE; INTERLEUKIN 1BETA; LIGAND; LIPOPOLYSACCHARIDE; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL LINEAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; LIGAND BINDING; MICROGLIA; MONOCYTE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR BLOCKING;

ASTROCYTES; BORNANES; CANNABINOIDS; CELL LINE; CYTOKINES; ENDOCANNABINOIDS; FORMAZANS; GENE EXPRESSION; HUMANS; INDOLES; INDOMETHACIN; L-LACTATE DEHYDROGENASE; LIGANDS; MICROGLIA; MONOCYTES; MORPHOLINES; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEMPORAL LOBE; TETRAHYDROCANNABINOL; TETRAZOLIUM SALTS;

EID: 0038678773     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705304     Document Type: Article

References (74)

1. BAKER, D., PRYCE, G., CROXFORD, J.L., BROWN, P., PERTWEE, R.G., HUFFMAN, J.W. & LAYWARD, L. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 404, 84-87.
2. BERDYSHEV, E.V. (2000). Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids, 108, 169-190.
3. 9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol., 330, 231-240.
4. BLEVINS, R.D. & REGAN, J.D. (1976). Delta-9-tetrahydrocannabinol: effect on macromolecular synthesis in human and other mammalian cells. Arch. Toxicol., 35, 127-135.
5. 2 receptor. Eur. J. Pharmacol., 396, 141-149.
6. CABRAL, G.A. & DOVE PETTIT, D.A. (1998). Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol., 83, 116-123.
7. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2, 69-82.
8. 9-tetrahydrocannabional. J. Neurosci., 18, 5322-5332.
9. CHANG, Y.H., LEE, S.T. & LIN, W.W. (2001). Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem., 81, 715-723.
10. COLTON, C.A., CHERNYSHEV, O.N., GILBERT, D.L. & VITEK, M.P. (2000). Microglial contribution to oxidative stress in Alzheimer's disease. Ann. NY Acad. Sci., 899, 292-307.
11. COMBS, C.K., JOHNSON, D.E., CANNADY, S.B., LEHMAN, T.M. & LANDRETH, G.E. (1999). Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins. J. Neurosci., 19, 928-939.
12. DAAKA, Y., KLEIN, T.W. & FRIEDMAN, H. (1995). Expression of cannabinoid receptor mRNA in murine and human leukocytes. Adv. Exp. Med. Biol., 373, 91-96.
13. DE GROOT, C.J.A., LANGEVELD, C.H., JONGENELEN, C.A.M., MONTAGNE, L., VAN DER VALK, P. & DIJKSTRA, C. (1997). Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization. J. Neurosci. Res., 49, 342-354.
14. DE GROOT, C.J.A., MONTAGNE, L., JANSSEN, I., RAVID, R., VAN DER VALK, P. & VEERHUIS, R. (2000). Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Res. Protocols, 5, 85-94.
15. DE PETROCELLIS, L., BISOGNO, T., MACCARRONE, M., DAVIS, J.B., FINAZZI-AGRO, A. & DI MARZO, V. (2001). The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 276, 12856-12863.
16. DECKER, T. & LOHMANN-MATTHES, M.L. (1988). A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods, 15, 61-69.
17. DENIS, M. (1994). Human monocytes/macrophages: NO or no NO? J. Leukocyte Biol., 55, 682-684.
18. DEWEY, W.L. (1986). Cannabinoid pharmacology. Pharmacol. Rev., 38, 151-178.
19. 2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
20. FACCI, L., DAL TOSO, R., ROMANELLO, S., BURIANI, A., SKAPER, S.D. & LEON, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A., 92, 3376-3380.
21. FELDER, C.C. & GLASS, M. (1998). Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol., 38, 179-200.
22. 9-tetrahydrocannabinol inhibition of tumor necrosis factor-α: suppression of post-translational events. J. Pharmacol. Exp. Ther., 267, 1558-1565.
23. GALIEGUE, S., MARY, S., MARCHAND, J., DUSSOSSOY, D., CARRIERE, D., CARAYON, P., BOUABOULA, M., SHIRE, D., LE FUR, G. & CASELLAS, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 54-61.
24. GALLANT, M., DUFRESNE, C., GAREAU, Y., GUAY, D., LEBLANC, Y., PRASIT, P., ROCHETTE, C., SAWYER, N., SLIPETZ, D.M., TREMBLAY, N., METTERS, K.M. & LABELLE, M. (1996). New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett., 6, 2263-2268.
25. GALLILY, R., YAMIN, A., WAKSMANN, Y., OVADIA, H., WEIDENFELD, J., BAR-JOSEPH, A., BIEGON, A., MECHOULAM, R. & SHOHAMI, E. (1997). Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther., 283, 918-924.
26. GIULIAN, D., VACA, K. & NOONAN, C.A. (1990). Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science, 250, 1593-1596.
27. GLASS, M. (2001). The role of cannabinoids in neurodegenerative diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 25, 743-765.
28. 2 receptors. Mol. Pharmacol., 56, 1362-1369.
29. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 292, 886-894.
30. GRIFFIN, G., WRAY, E.J., TAO, Q., MCALLISTER, S.D., RORRER, W.K., AUNG, M.M., MARTIN, B.R. & ABOOD, M.E. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol., 377, 117-125.
31. GUZMAN, M., SANCHEZ, C. & GALVE-ROPERH, I. (2001). Control of the cell survival/death decision by cannabinoids. J. Mol. Med., 78, 613-625.
32. HANSEN, M.B., NIELSEN, S.E. & BERG, K. (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods, 119, 203-210.
33. HILLARD, C.J. (2000). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins. Other Lipid Mediators, 61, 3-18.
34. HIRST, R.A. & LAMBERT, D.G. (1995). Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? Biochem. Soc. Trans., 23, 418S.
35. 1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse, 37, 71-80.
36. HOLM, S. (1979). A simple sequentially repetitive multiple test procedure. Scand. J. Statist., 6, 65-70.
37. HOWLETT, A.C. (1995). Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol., 35, 607-634.
38. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
39. HUFFMAN, J.W. (2000). The search for selective ligands for the CB2 receptor. Curr. Pharm. Design, 6, 1323-1337.
40. II, M., SUNAMOTO, M., OHNISHI, K. & ICHIMORI, Y. (1996). β-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res., 720, 93-100.
41. KLEGERIS, A. & MCGEER, P.L. (2002). Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging, 23, 789-796.
42. KLEGERIS, A. & MCGEER, P.L. (2000a). Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J. Leukocyte. Biol., 67, 127-133.
43. KLEGERIS, A. & MCGEER, P.L. (2000b). R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol., 166, 458-464.
44. KLEGERIS, A., WALKER, D.G. & MCGEER, P.L. (1999). Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology, 38, 1017-1025.
45. KLEIN, T.W., NEWTON, C. & FRIEDMAN, H. (1998). Cannabinoid receptors and immunity. Immunol. Today, 19, 373-381.
46. KOZAK, K.R., ROWLINSON, S.W. & MARNETT, L.J. (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem., 275, 33744-33749.
47. LEW, G.M. (1996). Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. Gen. Pharmacol., 27, 1141-1143.
48. LORTON, D., KOCSIS, J.-M., KING, L., MADDEN, K. & BRUNDEN, K.R. (1996). β-Amyloid induces increased release of interleukin-1β from lipopolysaccharide-activated human monocytes. J. Neuroimmunol., 67, 21-29.
49. MCCOY, K.L., MATVEYEVA, M., CARLISLE, S.J. & CABRAL, G.A. (1999). Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther., 289, 1620-1625.
50. MCMILLIAN, M., KONG, L.-Y., MULLIS-SAVIN, S., WILSON, B., DAS, K., HUDSON, P., HONG, J.-S. & BING, G. (1995). Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem. Biophys. Res. Commun., 215, 572-577.
51. MOLINA-HOLGADO, E., GUAZA, C., BORRELL, J. & MOLINA-HOLGADO, F. (1999). Effects of cannabinoids on the immune system and central nervous system. Therapeutic implications. BioDrugs, 12, 317-326.
52. MOSMANN, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
53. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
54. NEUROINFLAMMATION WORKING GROUP (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging, 21, 383-421.
55. NOWELL, K.W., PETTIT, D.A., CABRAL, W.A., ZIMMERMAN JR, H.W., ABOOD, M.E. & CABRAL, G.A. (1998). High-level expression of the human CB2 cannabinoid receptor using a baculovirus system. Biochem. Pharmacol., 55, 1893-1905.
56. 2 receptors. Pharmacol. Ther., 74, 129-180.
57. PIOMELLI, D., GIUFFRIDA, A., CALIGNANO, A. & RODRIGUEZ DE FONSECA, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218-224.
58. POPE, H.G. & YURGELUN-TODD, D. (1996). The residual cognitive effects of heavy marijuana use in college students. JAMA, 275, 521-527.
59. PORTER, A.C. & FELDER, C.C. (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Therapeut., 90, 45-60.
60. PUFFENBARGER, R.A., BOOTHE, A.C. & CABRAL, G.A. (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia, 29, 58-69.
61. ROBSON, P. (2001). Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiat., 178, 107-115.
62. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett., 436, 6-10.
63. SCALLET, A.C. (1991). Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol. Biochem. Behav., 40, 671-676.
64. 3. J. Leukoc. Biol., 59, 555-561.
65. 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci., 54, 1281-1289.
66. SHOWALTER, V.M., COMPTON, D.R., MARTIN, B.R. & ABOOD, M.E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989-999.
67. SOLOWIJ, N., STEPHENS, R.S., ROFFMAN, R.A., BABOR, T., KADDEN, R., MILLER, M., CHRISTIANSEN, K., MCREE, B., VENDETTI, J. & THE MARIJUANA TREATMENT PROJECT RESEARCH GROUP (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA, 287, 1123-1131.
68. STEFANO, G.B, LIU, Y. & GOLIGORSKY, M.S. (1996). Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem., 271, 19238-19242.
69. WAKSMAN, Y., OLSON, J.M., CARLISLE, S.J. & CABRAL, G.A. (1999). The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther., 288, 1357-1366.
70. WALKER, D.G., LUE, L.-F. & BEACH, T.G. (2001). Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol. Aging, 22, 957-966.
71. WELDON, D.T., ROGERS, S.D., GHILARDI, J.R., FINKE, M.P., CLEARY, J.P., O'HARE, E., ESLER, W.P., MAGGIO, J.E. & MANTYH, P.W. (1998). Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci., 18, 2161-2173.
72. WILEY, J.L., DEWEY, M.A., JEFFERSON, R.G., WINCKLER, R.L., BRIDGEN, D.T., WILLOUGHBY, K.A. & MARTIN, B.R. (2000). Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects. Life Sci., 67, 1573-1583.
73. YATES, S.L., BURGESS, L.H., KOCSIS-ANGLE, J., ANTAL, J.M., DORITY, M.D., EMBURY, P.B., PIOTRKOWSKI, A.M. & BRUNDEN, K.R. (2000). Amyloid β and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J. Neurochem., 74, 1017-1025.
74. ZHENG, Z.M., SPECTER, S. & FRIEDMAN, H. (1992). Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int. J. Immunopharmacol., 14, 1445-1452.